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Context: Production of 3-carbon units (as lactate) by granulosa cells (GC) is important in follicular 
and oocyte development, and may be modulated by metformin. 
Objective: To examine the action of metformin on GC lactate production and potential mediation via 
AMP-activated protein kinase (AMPK).   
Design: GC were prepared from follicular aspirates. After exposure to metformin and other potential 
modulators of AMPK in culture, aspects of cellular function were examined. 
Setting: Private fertility clinic/ University academic centre. 
Patients: Women undergoing routine in vitro fertilisation. 
Interventions:  All agents added in culture. 
 Main outcome measures: Lactate output of GC was measured.  Cell extracts were prepared after 
culture and phosphorylated forms of AMPK and acetyl CoA carboxylase (ACC) assayed using 
Western analysis. 
Results: Metformin led to a rapid increase in lactate production by GC (minimum effective dose, 
250µM; maximum dose studied, 1mM (1.22-fold; P<0.01)).  This dose range of metformin was 
similar to that required for stimulation of p-AMPK in GC (minimum effective dose, 250µM; 
maximum effect, 500µM (2.01-fold; P<0.001)).  Increasing p-ACC, as a representative downstream 
target regulated by AMPK, was apparent over a lower range (minimum effective dose, 31µM; 
maximum effect, 250µM; P<0.001).  A level of metformin (125µM) insufficient for the stimulation of 
lactate output when used alone, potentiated the effects of sub-optimal doses of insulin on lactate 
production.  Adiponectin (2.5µg/ml) had a small but significant effect on lactate output. 
Conclusions:  Metformin activates AMPK in GC, stimulating lactate production and increasing p-
ACC.  Metformin also enhances the action of sub-optimal insulin concentrations to stimulate lactate 
production. 
_______________________________________________________________ 
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women usually characterised 
by hyperandrogenism and oligomenorrhea (1).   Women with PCOS often exhibit insulin resistance, 
which contributes to an underlying mechanism important in the pathogenesis of PCOS (2).  This 
concept has led to the use of insulin sensitisers, such as metformin, in the treatment of PCOS.  
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Although the effectiveness of metformin treatment has proved variable, it is accepted that this 
compound can lead to improvements in symptoms associated with PCOS including a reduction in 
hyperandrogenism and a return to normal cycling within the ovary (3;4). 
  There is evidence that insulin resistance (associated with PCOS) may have an adverse effect on 
oocyte development and that, in in vitro fertilisation (IVF) cycles, this can lead to poor fertilisation of 
oocytes and poor developmental potential of resulting embryos (5).  There is some evidence that the 
use of metformin pre-conception in IVF cycles may ameliorate these adverse effects of insulin 
resistance, improving clinical pregnancy rates (4).  However, a clear and consistent clinical effect of 
metformin has been difficult to establish (6;7), with differential effectiveness of the drug reported 
according to the sub-group of PCOS patients studied (8). 
 
Granulosa cells (GC) and cumulus cells (in later stages of oocyte development) are required to 
provide products of glycolysis for the developing oocyte, which performs this pathway only poorly 
(9).  Although pyruvate is the key 3-carbon (3-C) intermediate transferred to the oocyte, it is likely 
that this is interchangeable with lactate which is the main 3-C unit produced by the GC.  A lack of 
insulin-stimulated lactate production in GC harvested from IVF cycles of women with PCOS (10;11) 
may therefore point to a fundamental problem with the provision of 3-C units for oocyte development 
during insulin resistance. 
It is established that metformin inhibits complex I of the respiratory chain thereby impairing 
mitochondrial function and cellular respiration (12;13).  This leads to a switch to anaerobic respiration 
which is presumed to be responsible for elevated plasma lactate concentrations in metformin-treated 
patients (14), and increased levels of lactate production by tissues exposed to metformin in vitro (15).  
How metformin influences lactate production by GC has not been previously established.  Clearly, 
metformin has the potential to increase lactate production by GC thereby reducing the shortfall in 3-C 
unit production experienced by follicular cells in insulin resistance, and improving ‘nutrition’ (with 
the supply of 3-C units) for the developing oocyte.  Adiponectin, a cytokine produced by adipose 
cells, appears to have similar downstream effects to metformin (16), and may also, therefore, play a 
physiological role in maintaining nutrient supply to the oocyte.  
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Many of the cellular effects of metformin are mediated by AMP activated protein kinase (AMPK; 
(17)).  AMPK is present in rat and bovine GC and appears to modulate the effects of metformin on 
steroidogenesis (18;19).  Effective doses of metformin used in these studies (approx 1-10mM) were 
much higher than those required to modulate steroidogenesis in human ovarian cells (20), and also 
higher than circulating levels of metformin during routine clinical treatment (reported to be 10-20 
µM; (21)).  There is a clear need to characterize AMPK activation in human GC with respect to 
concentrations of metformin required for activation of the enzyme and downstream events. 
The present study now addresses these issues firstly by investigating the effect of metformin on 
lactate production by human GC.  An observed stimulatory effect is then examined in relation to the 
activation of AMPK, and its potential downstream effects.  Implications of the study are discussed in 
terms of a potentially beneficial effect of metformin on 3-C unit supply to the oocyte. 
Subjects and methods 
Subjects 
The subjects participated in the study according to a protocol which had received local ethical 
approval and involved a procedure of written, informed consent.  The methodology involved 
collection of follicular aspirates obtained as part of the IVF procedure.  Patients were selected with no 
evidence of ovarian malfunction where infertility was ascribed to either tubal blockage or problems 
with the male partner.  Briefly, the treatment involved pituitary downregulation with a GnRH analog, 
induction of follicle growth with FSH, final maturation of follicles with hCG and 34h later, aspiration 
from follicles >15 mm in diameter (for details, see (22)).     
GC  preparation 
Following removal of the oocytes, the aspirates (and washes) for each patient were combined and 
brought to the laboratory.  Initially, GC were prepared according to a previously published method 
(22) where white blood cell contaminants were removed using antibody-bound magnetic beads, 
reducing white cell content to <1% of total cells.  This led to a final GC suspension of approximately 
105 cells/ml.  For subsequent experiments, a simpler method of preparation, involving the removal of 
blood contaminants through the use of ‘cell strainers’, was developed as follows (providing more 
tissue required for Westerns and shorter-term incubations).  Aspirates were first ‘strained’ through 40 
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µm ‘cell strainers’ (BD Biosciences, Oxford, UK), which retained cell clusters of GC.  After rinsing 
to remove the last traces of blood contaminants, the strainers were back-washed with medium which 
was a mixture (50:50) of DMEM and Ham’s F12 (Invitrogen, Paisley, UK), containing 10% fetal 
bovine serum, glutamine (2 mmol/l), penicillin (100,000 IU/l), streptomycin (100 mg/l), and 
amphotericin (0.25 mg/l).  The resulting suspension (approx. 12 ml) was incubated at 37oC in 5% CO2 
in air for 3-4h, aspirated repeatedly through a fine ‘pastette’ (dispersing the clusters of GC) and then 
strained through a 70 µm ‘cell strainer’ (BD Sciences) to remove undispersed material.  The 
suspension was diluted with about 30 ml of additional medium, centrifuged at 1200 rpm for 10 min, 
and the cell pellet resuspended, counted with a haemocytometer and then diluted to approx. 2-4 x 105 
cells/ml.  White cell content was estimated by a previously published method (22) and was routinely 
<5% of total cells.  Viability, estimated by trypan blue exclusion, was routinely >95% and cells were 
present largely as small clusters.  In general, the cells showed good attachment in subsequent culture.  
Omission of the ‘washing’ effect of the prior ‘3-4 h incubation/dilution/centrifugation’ steps led to a 
variable ability of the cells to attach.  Aliquots (1 ml) of cell suspension were dispensed into wells of a 
24-well culture dish and cultured overnight at 37oC in 5% CO2 in air, allowing attachment to the 
plastic culture surface.   
Culture of GC with additions 
Both methods for preparation led to a final culture in a defined medium where the serum component 
was substituted with transferrin (5 mg/ l), selenite (25 nmol/l) and albumin (500 mg/l; Elisa grade 
with low insulin concentration; Sigma, Poole, UK).  Additions to cultures, formulated in defined 
medium, were as described in legends.  5-Aminoimidazole-4-carboximide-1-β-D-ribofuranosyl 5’-
monophosphate (AICAR) and metformin were purchased from Sigma, and recombinant human 
adiponectin was from Peprotech (London, UK).  Culture with additions continued for times indicated 
in legends.   
Lactate assay 
After culture, lactate was measured in 10 µl culture medium by a method previously described (22) 
which involved the use of a lactate oxidase/peroxidase reagent (Trinity Biotech, Theale, UK). 
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Western analysis of phosphorylated forms of AMPK and acetyl CoA carboxylase (ACC) 
Immediately after culture, the culture plate with adherent cells was placed on crushed ice prior to the 
addition to each well of 0.25 ml of ice-cold extraction medium (100 mM Tris/HCl (pH 7.4), 10 mM 
sodium pyrophosphate, 2 mM EDTA, 2 mM EGTA, 100 mM sodium fluoride, 2% (v/v) protease 
inhibitor cocktail (Sigma No: P8340), 2% (v/v), Triton X-100, and 2 mM orthovanadate).  The surface 
of each well was scraped with a pipette tip, the contents of each well transferred to a small tube and 
immediately frozen in dry ice.  Each tube was then thawed, immediately homogenised using a rotating 
probe (Biospec Products, Bartlesville, US.), dispensed into 50 µl aliquots and rapidly re-frozen before 
storage at -80oC. 
On the day of electrophoresis, aliquots were thawed on ice before the addition of 50 µl of 2x sample 
buffer (125 mM Tris/HCl (pH 6.8), 4% (w/v) sodium dodecyl sulphate (SDS), 10% (w/w) glycerol, 
0.006 % (w/v) bromophenol blue and 40 mM dithiothreitol).  Tubes were mixed and heated for 10 
min at 95oC.   Samples (50 µl per lane; approx. 20 µg protein) were loaded on to commercially 
prepared 7.5% polyacrylamide gels (Bio-Rad, Hemel Hempstead, UK) together with stained, standard 
molecular weight protein markers in an adjacent lane.  Samples generated as part of one culture 
experiment were always run simultaneously and ‘between-well’ variation in loading was <10%.  Gels 
were run at 90 V in buffer which was 25 mM Tris/HCl, 192 mM glycine and 0.1% (w/v) SDS.  
Blotting on to PVDF membrane was carried out using a semi-dry blotter (Bio-Rad) with transfer 
buffer which was 25 mM Tris/HCl, 192 mM glycine, 0.037% (w/v) SDS and 20 % methanol.  
Membranes were blocked overnight at 4oC in 2% (w/v) blocker (provided as part of the ECL Advance 
kit, GE Healthcare, Amersham) made up in ‘tris-buffered saline-tween’ (TBST; 10 mM Tris/HCl (pH 
7.6), 0.14 M NaCl and 1% (v/v) Tween).  Blots were exposed overnight at 4oC on a roller to primary 
antibodies dissolved in 2% (w/v) bovine serum albumin (BSA) in TBST.  Primary antibodies used 
separately (all raised in rabbits and purchased from Millipore, Chandlers Ford, UK) were anti-
phospho-AMPKα (thr172; 1:2000 dilution), anti-AMPKα2 (used at 1 µg/ml), anti-AMPKα1 (used at 
1 µg/ml), and anti-phospho-ACC (Ser 79; used at 0.5 µg/ml).  After washing repeatedly in TBST, 
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blots were then exposed for 1h at room temperature to the secondary antibody which was goat anti-
rabbit IgG, HRP-conjugate (Millipore; 1:3000 dilution in TBST with 2% (w/v) BSA).   After rinsing 
in TBST, blots were developed using the ECL Advance reagent and analysed using the Bio-Rad 
Versadoc system which enabled quantification of the relevant bands.  Preliminary development work 
on GC extracts with the several anti-AMPK antibodies showed that the phosphorylated form of 
AMPK co-migrated (at a position equivalent to about 63kD) with a band of α1-AMPK (confirming 
their identities; Fig. 2C).  The α2-AMPK isoform was not detected in the GC extracts. 
Progesterone assay 
This was quantified using an in-house semi-automatic immunoassay involving detection of 
chemiluminescence (22). 
Results 
Initial culture experiments on metformin and lactate production 
The effect of adding metformin (500 µM) to overnight cultures of GC, purified free of white cells 
according to our previously described method (22), is shown in Fig. 1.  A significant stimulatory 
effect of metformin on lactate production was observed (N=10 cultures, P<0.002 vs equivalent 
condition without metformin) irrespective of whether cells were cultured with or without additional 
hormones (maximal concentrations of either hCG or insulin, each of which upregulates lactate 
production (22)).  These experiments also showed a significant inhibitory effect of metformin on 
hCG-stimulated progesterone production (Fig. 1, insert). 
Time course studies 
 Having performed our initial experiments using the previously published method (22), the simpler 
method involving removal of blood cell contaminants by ‘cell straining’ was now employed providing 
more cellular material for Western analysis, and allowing culture experiments to be carried out over 
shorter time periods.  Our new methodology allowed the measurement of the effect on lactate 
production after only 3h exposure to metformin (Fig. 2A; concn, 500µM).  An equivalent time course 
of action on lactate production by GC was observed for AICAR (Fig 2B; concn, 4 mM), a compound 
known to activate AMPK.  A broadly similar interval between addition of metformin and activation of 
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AMPK was observed (Fig. 2C and D), where the effect was becoming clearly established over 3-4.5h. 
Consequently, dose-response studies were standardised to a 4.5h period. 
Dose-response studies 
At 4.5h, media from GC cultures, previously exposed to a range of metformin concentrations, were 
collected and measured for lactate (Fig. 3A; N=6 experiments). Also, cells were harvested, 
homogenised and subjected to Western analysis for the phosphorylated α-subunit of AMPK (Fig. 3B; 
N=10) and phosphorylated-ACC (Fig.3C; N=5).  A clear, and significant, stimulatory effect on lactate 
production was observed at metformin concentrations of 250µM and above (Fig 3A).  The 
concomitant effect on AMPK activation (Fig. 3B) showed a similar overall pattern with significant 
stimulation at 250µM and above, although variation in the response between patients was 
considerable as illustrated by the error bars.  The pattern of phosphorylation of ACC over the dose 
range of metformin (Fig. 3C) was very different with significant increases at 31µM, as the effect 
became established at low concentrations of the drug which were not sufficient to elicit changes in 
lactate.  Although the ‘minimum dose to elicit a significant change’ was clearly different for AMPK 
and ACC, it should be noted that small changes in AMPK may have occurred at doses of metformin 
less than 250µM but that  these were masked by experimental variability. 
Effect of metformin on sub-maximal insulin concentrations 
With evidence that at least one downstream effect of AMPK activation was being triggered at lower 
concentrations of metformin, we investigated the effect of low-dose metformin on the characteristics 
of insulin action knowing that results would be unaffected by metformin-alone effects on lactate 
production.  Thus, after a 4.5h exposure to 125µM metformin (a dose with no effect on lactate 
production when used alone) there was a significant (up to P<0.01) stimulatory effect of the drug on 
lactate production induced by sub-optimal concentrations of insulin (continued overnight) with the 
most significant effect seen at 3ng insulin/ml (Fig. 4).   
Effect of adiponectin on lactate production 
Addition of adiponectin (2.5µg/ml) to GC in culture led to a significant elevation in lactate production 
(Fig.5) although this was only about 10-20% of the much stronger stimulation of lactate production 
induced by maximal hCG (100 ng/ml).  The two effects (maximal hCG and adiponectin) were not 
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additive (see last column).  Attempts to demonstrate a significant change in p-AMPK at this 
adiponectin concentration gave equivocal results (data not shown).     
Discussion 
Metformin causes a shift towards anaerobic respiration leading to increased lactate output by tissues 
(14;15).  Our novel data now establish that this general principle, well exemplified by work on rat 
muscle (15), extends to human GC which showed a marked increase in lactate production on exposure 
to 500 µM metformin (Fig.1).  When GC lactate production was maximally upregulated with either 
hCG or insulin, the effect of metformin persisted suggesting that its mechanism of action is different 
from that of these agonists.  The concomitant decrease in hCG-stimulated steroid production with 
metformin (insert to Fig.1) is consistent with previous work on human GC (20) and similar effects in 
animal species (18;19) . 
Our preliminary investigations on the role of AMPK in GC confirmed its presence in the cell extracts 
in agreement with previous work on rat and bovine GC (18;23).  The pre-dominance of the α1-subunit 
(see Methods) is consistent with previous work on rat ovary (23).  Time course studies with 
metformin and AICAR (Fig.2) revealed features of the control of lactate production by GC.  
Certainly, the stimulatory effect of AICAR (Fig. 2B) demonstrates that elevation of AMPK activity in 
GC leads to increases in lactate output presumably through effects on glucose uptake and/or 
glycolysis (24).  This may be analogous to increases in lactate production by GC resulting from 
insulin-induced elevation of glucose uptake (11).   Previous work has demonstrated that metformin 
quickly penetrates cells with end-effects on cell respiration measurable within 1h (13).  AICAR has 
also been shown to stimulate intracellular AMPK within 1h (23).  Our human GC preparation appears 
to have an extra time delay built into the system with onset of lactate responses to metformin and 
AICAR (Figs 2A and B), and activation of AMPK with metformin (Fig. 2C and D) all measurable 
after about 3h. 
Explaining metformin dose-response relationships can be problematic as levels used for in vitro work 
are often high compared with normal levels of exposure during clinical treatment.  Certainly, 
treatment in vivo (where the circulating concentrations are 10-20µM) may be accompanied by slow 
accumulation within tissues (21).  This may partially explain why higher levels are needed in short 
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term incubations in vitro where time is not available for accumulation.  In the present study, effective 
levels of metformin with regard to lactate production (Fig 3A) and AMPK activation (Fig. 3B) were 
250µM and above, and were broadly in line with concentrations used in previous studies on rat GC 
(e.g., (18)). The close parallel between these two parameters is consistent with a causative link 
between p-AMPK and lactate output.   However, much lower concentrations of metformin (approx. 
30µM and above) were effective with regard to ACC phosphorylation (Fig. 3c) suggesting that 
downstream effects of AMPK may be manifest at concentrations of metformin below the threshold 
for lactate production.  The explanation for this is obscure but may be to do with the considerable 
between-patient variability in levels of p-AMPK at lower doses of metformin, which could hide small 
but important changes in activity.  We speculate that there is magnification built into the AMPK 
cascade whereby small changes in p-AMPK lead to larger changes in downstream events.  Our 
observations may offer a partial explanation for the report by Mansfield et al. (20) which described 
effective doses of metformin in the sub-micromolar range, although further allowance would be 
needed for accumulation of the drug in the extended culture of 48h used in that study. 
 
It is established that AMPK has a wide range of targets within cells so that activation has the 
combined effect of increasing energy supply and decreasing energy consumption in macromolecular 
synthesis (24).  We argue that the lower concentration range of metformin required for increasing p-
ACC in GC may provide a guide to the levels of the drug required for this wider range of target 
alterations.  It has been suggested that one such target lies within a mechanism governing insulin 
sensitivity such that metformin is able to increase sensitivity to insulin with regard to glucose disposal 
in muscle (reviewed by (25)).  Our finding shown in Fig. 4 that the effect on GC of sub-optimal doses 
of insulin appears to be potentiated by metformin at a concentration (125 µM) unable to stimulate 
lactate production when used alone (Fig. 3A), shows that this mechanism may apply in GC (like 
skeletal muscle) and provides extra evidence for our assertion that p-ACC provides a guide to the 
alterations of other AMPK targets despite being associated with minimal overall changes in p-AMPK 
at lower concentrations of metformin. 
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The interaction of metformin and insulin action on GC is emerging as a mixed picture.  On the one 
hand, it is clear that metformin has the potential to reinforce the action of sub-optimal doses of insulin 
on lactate production (probably through an effect on glucose uptake).  On the other, an inhibition of 
fatty acid synthesis through increasing p-ACC would tend to offset any positive effect of insulin on 
fatty acid synthesis through increasing SREBP-1c as previously observed in this laboratory (19).   
 
There are parallels between the modes of action of metformin and the naturally occurring 
adipocytokine, adiponectin, as both appear to operate through stimulation of AMPK to enhance 
insulin action (16).    It was difficult to arrive at an appropriate level of adiponectin to include in 
cultures of GC as adiponectin circulates over a considerable concentration range in humans (3-30 
µg/ml) and is present in a number of molecular forms (26).  Using 2.5µg/ml we nevertheless observed 
a significant effect on lactate output (Fig. 5)  though the effect was lower than the strong effect of 
hCG expected in this system (22).  The observation that the effects of the two agents, adiponectin and 
hCG, were not additive suggests that their modes of action are different.   Our results are consistent 
with the observed presence of adiponectin receptors in rat ovarian tissue (27) and human GC 
(unpublished work of this laboratory), and point to a physiological role for adiponectin in ovarian 
function.  Perhaps our work on metformin acts as a model system for how adiponectin might facilitate 
insulin action in the ovary.   
 
It is difficult to extrapolate from in vitro findings to the situation in vivo, where 3-C unit production 
for the oocyte will be influenced by a complex range of factors including insulin, gonadotrophins, 
oocyte maturation and follicle size (28-30).  For example, measurements of glucose and lactate in 
follicular fluids obtained from PCOS patients with increased insulin resistance (based on average 
figures for the group vs controls) do not appear to show a disordered relationship between these two 
metabolites in PCOS (31).  Also, measurements of follicular components in obese, normoandrogenic 
women with raised circulating and follicular insulin, failed to show concomitant changes in follicular 
glucose and lactate (32).  These in vivo studies contrast with two independent studies showing lack of 
insulin-induced lactate production in vitro by GC from follicles of women with PCOS (10;11).       
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Recognising these difficulties we put forward the following schema (shown in Fig. 6), based on the in 
vitro evidence, which attempts to put our work into context.  The oocyte performs glycolysis only 
poorly and depends on the provision of 3-C units through the agency of the surrounding cumulus 
cells.  Because cumulus cells appear to have the ability to use imported lactate to make pyruvate 
(discussed by (9)), we suggest that lactate generally within the follicle (mostly made by the GC; (30)) 
may form part of a co-ordinated system for transferring 3-C units to the oocyte.  The metabolism of 
GC within follicles appears to be almost entirely anaerobic with 2 molecules of lactate being produced 
from each molecule of glucose taken in (28).  Consequently, the drive to supply 3-C ‘nutrient’ to the 
oocyte must be very dependent on insulin-enabled glucose uptake by follicular cells.  In insulin 
resistance, the transfer of 3-C units to the oocyte is compromised (10;11) and this can lead to 
problems with oocyte development .  Our work, now shows that up-regulation of AMPK with 
metformin (or through the physiological impact of adiponectin) could potentially increase lactate 
production oncemore (Fig.6).  It should be stressed that the present study has not used cells from 
patients with PCOS and therefore has not tested directly the central idea shown in figure 6.  However, 
our work suggests the need for further studies on GC specifically linked to data on insulin resistance 
of the donor patients.  In this way, the impact of whole-body insulin resistance on GC could be 
determined and the potential for the reversal of deficiencies with metformin established.  Despite the 
limitations of our study, it provides a potential and testable rationale for the observed effects of 
metformin therapy (4) in the treatment of PCOS.      
   
In summary we have shown that metformin acts on human GC by activating AMPK and that this is 
associated with an increase in lactate output.  A number of downstream targets of AMPK are altered 
including ACC and a mechanism governing responses to sub-optimal levels of insulin. 
 
The authors acknowledge the valuable contribution of the embryologists (particularly Anthony Price) 
at Wessex Fertility, for help in collecting the follicular aspirates.   
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FIG. 1. Effect of metformin (500µM) on lactate production by human GC.  Cultures were for 16h 
without additional hormones (control), with maximal hCG (100 ng/ml), or with maximal insulin 
(1000ng/ml), and were either with metformin (hatched bars) or without (open bars).  Lactate 
output is expressed as percent of control values (without metformin).  Insert shows equivalent 
values for progesterone expressed as nmol/l.  Bars represent means (with SEM; n=10 
experiments for lactate and n=4 for progesterone).  *, P<0.05; **, P<0.002 vs. equivalent 
condition without metformin (paired t-test). 
 
 
FIG. 2. Short-term time course studies on the effect of metformin (500µM) and AICAR (4mM) on 
lactate output by GC, compared with the onset of metformin-induced activation of AMPK.   A), 
Effect of metformin (dashed line) on lactate vs control (solid line). B), Effect of AICAR 
(dashed line) on lactate vs control (solid line). Error bars (some too small to be visible) show 
SEMs reflecting variation within the typical experiment shown.  C), Western blot showing  α1-
subunit (α1-) of AMPK in non-incubated cells (left-hand panel) and blot showing p-AMPK 
(right-hand panel) increasing after 500µM metformin treatment and D), values for p-AMPK, 
calculated through image analysis of the bands visible on blot C, for metformin treatment 
(dashed line) vs control (solid line).  `. 
 
FIG. 3.  Dose-response relationships for metformin action on GC with regard to lactate output (A), 
AMPK activity as reflected by p-AMPK (B), and phosphorylation of ACC (D) as an accepted, 
representative downstream target for AMPK.  Lactate is expressed as percent of control (no 
metformin) whereas p-AMPK and p-ACC are as percent of maximum response measured in 
each experiment.  Values represent means (with SEM; n=6 experiments for lactate, n=10 for p-
AMPK and n=5 for p-ACC).  *, P<0.05; **, P<0.01; ***, P<0.001 vs control (paired t-test). 
 
FIG. 4. Effect 125µM metformin (insufficient to cause lactate increase when used alone) on GC 
lactate output in the presence of a range of concentrations of insulin.  The GC were incubated 
with metformin for 4.5h before addition of the insulin and then cultured for 16h with the insulin 
and metformin where appropriate.  Values represent means (with SEM; N=6).  P values shown 
and calculated as in previous legend. 
 
FIG. 5.  A comparison of the effects of adiponectin (2.5µg/ml), maximal hCG (100ng/ml), and both 
agonists together on lactate production by GC.  Bars represent means (with SEM; n=6 
experiments).  *, P<0.05 vs control (paired t-test). 
 
FIG. 6.  Delivery of 3-C units to the oocyte.  We envisage insulin-dependent glucose (G) uptake by 
both GC and cumulus cells.  Through respiration which is predominantly anaerobic, G is 
converted to pyruvate (P) which is interchangeable with lactate (L) through the agency of lactic 
dehydrogenase.  Large quantities of L subsequently released into the follicular fluid should be 
available to the cumulus cells for conversion back to P and for transfer to the developing 
oocyte, augmenting the intrinsic capacity of cumulus cells to produce P.  Under normal 
conditions of insulin sensitivity, there is efficient delivery of 3-C units to the oocyte.  In insulin 
resistance, the action of insulin to sustain glucose uptake is reduced so that efficient production 
of 3-C units is compromised.  Clearly, activation by metformin or adiponectin of AMPK has the 
potential to increase oncemore the delivery of 3-C units to the oocyte mitigating the effects of 
insulin resistance. 
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A) Normal physiological situation giving efficient drive of 3-C unit delivery to oocyte:
B) In insulin resistance, the action of insulin to sustain glucose uptake is 
reduced so that delivery of 3-C units to the oocyte is compromised.
C) AMPK activators (metformin/adiponectin) can restore delivery.
